Pregled bibliografske jedinice broj: 277117
INTRAVENOUS AZITHROMYCIN COMBINED WITH BETA-LACTAM ANTIBIOTICS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA – AN INTENSIVIST PERSPECTIVE
INTRAVENOUS AZITHROMYCIN COMBINED WITH BETA-LACTAM ANTIBIOTICS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA – AN INTENSIVIST PERSPECTIVE // 15th European Congress of Clinical Microbiology and Infectious Diseases
Kopenhagen, Danska, 2005. (pozvano predavanje, nije recenziran, sažetak, znanstveni)
CROSBI ID: 277117 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
INTRAVENOUS AZITHROMYCIN COMBINED WITH BETA-LACTAM ANTIBIOTICS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA – AN INTENSIVIST PERSPECTIVE
Autori
Baršić, Bruno
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
15th European Congress of Clinical Microbiology and Infectious Diseases
Mjesto i datum
Kopenhagen, Danska, 02.04.2005. - 05.04.2005
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Nije recenziran
Ključne riječi
community-acquired pneumonia; combined treatment; azithromycin
Sažetak
Severe pneumonia treated in intensive care units (ICU) represents a great therapeutic challenge. Usual defervescence of fever does not occur as in other patients, particularly not in mechanically ventilated patients. We evaluated 30 consecutive patients with community acquired pneumonia admitted in the ICU. Initial therapy was azithromycin intravenously for seven days plus beta-lactams (ceftriaxon or penicillin). Switch to oral treatment was possible after defervescence of fever. Treatment was finished as planned in 25 patients. In five patients it was stopped because of early therapeutic failure, isolation of resistant pathogens or adverse drug event. However, in 10/25 patients which completed planned treatment additional antibiotics were added despite improvement of pneumonia because of suspected or confirmed nosocomial infection. Six patients died during hospitalisation. Treatment beta-lactams plus azithromycin was successful in 21 patients. Analysis of duration of fever in survivors showed that only in one patient defervescence of fever occurred after three days of treatment. Our results suggest that randomised clinical studies overestimate clinical efficacy of antibiotics due to the selection of patients, even with severe pneumonia. Evaluation of treatment effect should be based more on meticulous estimation of respiratory function than on parameters representing systemic inflammatory response or x-ray findings.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
